Next 10 |
home / stock / spgi / spgi articles
S&P Global Inc. (NYSE:SPGI) disclosed today the election of Martina L. Cheung, current President of S&P Global Ratings, to succeed Douglas ...
S&P Global (NYSE:SPGI) has outperformed the market over the past 10 years by 7.13% on an annualized basis producing an average annual return of...
Joseph M. Terranova of Virtus Investment Partners picked Datadog, Inc. (NASDAQ:DDOG) as his final trade on the Thursday edition of CNBC's R...
C.H. Robinson (NASDAQ: CHRW) has had its credit rating downgraded for the first time in at least six years, but its latest rating of BBB, down fro...
S&P Global (NYSE:SPGI) has outperformed the market over the past 10 years by 7.91% on an annualized basis producing an average annual return of...
S&P Global Inc. (NYSE:SPGI) reported its first-quarter financial results before the bell Thursday. Here's a look at the highlights. ...
NEW YORK, April 23, 2024 /PRNewswire/ -- automotiveMastermind, the automotive industry's trusted data and technology provider, will integrate ...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
S&P Global (NYSE:SPGI) has outperformed the market over the past 10 years by 7.71% on an annualized basis producing an average annual return of...
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 10:15:02 ET BMO Capital analyst issues OUTPERFORM recommendation for SPGI on July 2, 2024 08:38AM ET. The previous analyst recommendation was Outperform. SPGI was trading at $446.32 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
S&P Global Schedules Second Quarter 2024 Earnings Announcement and Conference Call for Tuesday, July 30, 2024 S&P Global Schedules Second Quarter 2024 Earnings Announcement and Conference Call for Tuesday, July 30, 2024 PR Newswire NEW YORK , June 28, 202...
Protagonist Therapeutics Set to Join S&P SmallCap 600 Protagonist Therapeutics Set to Join S&P SmallCap 600 PR Newswire NEW YORK , June 27, 2024 /PRNewswire/ -- Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in ...